Zoledronic and Osgood-schlatter disease - a phase IV clinical study of FDA data

Summary:

Osgood-schlatter disease is reported as a side effect among people who take Zoledronic (zoledronic acid), especially for people who are female, 50-59 old, also take Eliquis, and have Breast cancer.

The phase IV clinical study analyzes which people have Osgood-schlatter disease when taking Zoledronic. It is created by eHealthMe based on reports of 29,760 people who have side effects when taking Zoledronic from the FDA, and is updated regularly.

What is Zoledronic?

Zoledronic has active ingredients of zoledronic acid. eHealthMe is studying from 29,812 Zoledronic users. Check the latest studies of Zoledronic.

What is Osgood-schlatter disease?

Osgood-schlatter disease (an overuse injury that occurs in the knee area of growing adolescents. it is caused by inflammation of the tendon below the kneecap) is found to be associated with 308 drugs and 353 conditions by eHealthMe. Check the latest studies of Osgood-schlatter disease.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

29,760 people reported to have side effects when taking Zoledronic.
Among them, 31 people (0.1%) have Osgood-schlatter disease.

Could Zoledronic cause Osgood-schlatter disease?

Among these 31 people:

What is the gender of people who have Osgood-schlatter disease when taking Zoledronic? *

female: 100 %
male: 0.0 %

What is the age of people who have Osgood-schlatter disease when taking Zoledronic? *

What are other drugs people take besides Zoledronic? *

What are other side effects people have besides Osgood-schlatter disease? *

Vulvovaginal Dryness: 30 people, 96.77%
Taste - Impaired: 30 people, 96.77%
Left Ventricular Dysfunction: 30 people, 96.77%
Dry Skin: 30 people, 96.77%
Back Pain: 30 people, 96.77%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 30 people, 96.77%
Anaemia (lack of blood): 30 people, 96.77%
Abdominal Pain Upper: 30 people, 96.77%
Dizziness: 17 people, 54.84%
Chest Pain: 17 people, 54.84%

What are the existing conditions these people have? *

Breast Cancer: 31 people, 100.00%
Metastases To Bone (cancer spreads to bone): 30 people, 96.77%
Dry Skin: 2 people, 6.45%
Back Pain: 2 people, 6.45%
Anaemia (lack of blood): 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Zoledronic and have Osgood-schlatter disease?

- Check whether Osgood-schlatter disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zoledronic:

Zoledronic (29,812 reports)

Browse all side effects of Zoledronic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osgood-schlatter disease:

Osgood-schlatter disease (308 drugs)

Browse all the conditions that are associated with Osgood-schlatter disease:

Osgood-schlatter disease (353 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zoledronic) and Zoledronic (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.